Search all trials

Find therapies in clinical trials near you – page 2

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 961
countries: 28
conditions: 2 103

3 961 trials recruiting28 European countries2 103 conditions coveredUpdated today

Quick filters

Non-small cell lung cancer metastatic+1

Recruiting

Registered drugNo placebo

A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:ASP3082

Contact Research Centre

Non-small cell lung cancer metastatic+2

Recruiting

Registered drug

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Registered drugNo placebo

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Osimertinib

Contact Research Centre

Non-small cell lung cancer metastatic+2

Recruiting

Registered drugNo placebo

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Budesonide

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Registered drug

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drug

Austria

Participants:18–64 years · 65+ years
Substances:Adagrasib

Contact Research Centre

Non-small cell lung cancer metastatic+3

Recruiting

Registered drugNo placebo

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Budigalimab

Contact Research Centre

Non-small cell lung cancer metastatic+1

Recruiting

InvestigationalNo placebo

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:VERT-002

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

InvestigationalNo placebo

Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:Stx-241

Contact Research Centre

Non-small cell lung cancer metastatic+1

Recruiting

Registered drugNo placebo

Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Non-small cell lung cancer metastatic+5

Recruiting

InvestigationalNo placebo

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan

Contact Research Centre

Non-small cell lung cancer metastatic

Recruiting

Registered drugNo placebo

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo

Czechia

Participants:18–64 years · 65+ years
Substances:Acetylsalicylic Acid

Contact Research Centre

Non-small cell lung cancer metastatic+1

Recruiting

Registered drugNo placebo

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Aldesleukin

Contact Research Centre

Find therapies in clinical trials near you – page 2

82 trials match your criteria

Non-small cell lung cancer metastatic+1

A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

Non-small cell lung cancer metastatic+2

A Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment

Non-small cell lung cancer metastatic

Study of Different Dosing Schedules of Osimertinib in Patients with EGFR Mutated Advanced or Metastatic Non-Small Cell Lung Cancer

Non-small cell lung cancer metastatic+2

Study of divarasib and pembrolizumab compared to standard chemotherapy in previously untreated KRAS G12C-mutated advanced non-small cell lung cancer

Non-small cell lung cancer metastatic

Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Non-small cell lung cancer metastatic+3

Study of ABBV-400 and Budigalimab for Adults with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Non-small cell lung cancer metastatic+1

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

Non-small cell lung cancer metastatic

Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

Non-small cell lung cancer metastatic+1

Study of Durvalumab, Tremelimumab, Chemotherapy, and Radiotherapy for Patients with Newly Diagnosed Non-Small Cell Lung Cancer with Limited Spread

Non-small cell lung cancer metastatic+5

Study on Long-Term Safety of Trastuzumab Deruxtecan for Patients with Advanced HER2-Positive or HER2-Mutated Solid Tumors

Non-small cell lung cancer metastatic

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Non-small cell lung cancer metastatic+1

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.